The interaction between methylene blue and the cholinergic system.
1. The inhibitory effects of methylene blue (MB) on different types of cholinesterases and [3H]-N-methylscopolamine ([3H]-NMS) binding to muscarinic receptors were studied. 2. Human plasma from young healthy male volunteers, purified human pseudocholinesterase and purified bovine true acetylcholinesterase were incubated with acetylcholine and increasing concentrations of MB (0.1-100 mumol l-1) in the presence of the pH-indicator m-nitrophenol for 30 min at 25 degrees C. The amount of acetic acid produced by the enzymatic hydrolysis of acetylcholine was determined photometrically. 3. Rat cardiac left ventricle homogenate was incubated with [3H]-NMS and with increasing concentrations of MB (0.1 mmol l-1 mumol l-1) at 37 degrees C for 20 min. THe binding of [3H]-NMS to the homogenate was quantified by a standard liquid scintillation technique. 4. MB inhibited the esterase activity of human plasma, human pseudocholinesterase and bovine acetylcholinesterase concentration-dependently with IC50 values of 1.05 +/- 0.05 mumol l-1, 5.32 +/- 0.36 mumol l-1 and 0.42 +/- 0.09 mumol l-1, respectively. MB induced complete inhibition of the esterase activity of human plasma and human pseudocholinesterase, whereas bovine acetylcholinesterase was maximally inhibited by 73 +/- 3.3%. 5. MB was able to inhibit specific [3H]-NMS binding to rat cardiac left ventricle homogenate completely with an IC50 value of 0.77 +/- 0.03 mumol l-1, which resulted in a Ki value for MB of 0.58 +/- 0.02 mumol l-1. 6. In conclusion, MB may be considered as a cholinesterase inhibitor with additional, relevant affinity for muscarinic binding sites at concentrations at which MB is used for investigations into the endothelial system. In our opinion these interactions between MB and the cholinergic system invalidate the use of MB as a tool for the investigation of the L-arginine-NO-pathway, in particular when muscarinic receptor stimulation is involved.
Pfaffendorf
M
M
Department of Pharmacology, University of Amsterdam, The Netherlands.
Bruning
T A
TA
Batnik
H D
HD
van Zwieten
P A
PA
D000110:Acetylcholinesterase / Q000097:blood / Q000187:drug effects* / Q000378:metabolism; D000328:Adult; D000818:Animals; D002091:Butyrylcholinesterase / Q000097:blood / Q000187:drug effects* / Q000378:metabolism; D002417:Cattle; D002800:Cholinesterase Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D004950:Esterases / Q000097:blood; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D008297:Male; D008751:Methylene Blue / Q000378:metabolism / Q000494:pharmacology*; D009206:Myocardium / Q000378:metabolism; D019832:N-Methylscopolamine; D010276:Parasympatholytics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism; D012602:Scopolamine Derivatives / Q000378:metabolism; D014316:Tritium
D002800:Cholinesterase Inhibitors; D010276:Parasympatholytics; D011976:Receptors, Muscarinic; D012602:Scopolamine Derivatives; D014316:Tritium; D004950:Esterases; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase; D008751:Methylene Blue; D019832:N-Methylscopolamine